Loading...
Loading...
SLRX| Name | Value |
|---|---|
| Revenues | 17.9K |
| Cost of Revenue | 1.1K |
| Gross Profit | 16.8K |
| Operating Expense | 969.6K |
| Operating I/L | -970.7K |
| Other Income/Expense | 88.9K |
| Interest Income | 88.9K |
| Pretax | -881.8K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -881.8K |
Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in epigenetic-based cancer treatments. Its lead candidate, Seclidemstat (SP-2577), is a small molecular inhibitor in Phase I/II clinical trials for advanced solid tumors and Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for hematological and solid tumors. Salarius has strategic partnerships for exclusive licenses, development, production, and research activities with various organizations to advance its drug candidates and identify new indications and biomarkers. These partnerships contribute to the company's revenue streams and potential future commercialization of its products.
